All News
The History of Citrullination (Best of 2015)
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read Article
Will the Balance of JAK inhibition Yield Better Outcomes? Results of New JAK inhibitor - Peficitinib
Researchers from Keio University have published their results using novel JAK inhibitor peficitinib (ASP015K) as a monotherapy in moderate to severe RA patients.
Read Article
Predicting and Preventing Rheumatoid Arthritis
Rheumatologists and physicians are commonly asked, "what can I do to avoid rheumatoid arthritis?" This is usually a concern for family members of those affected by RA.
Read Article
Herpes Zoster Increases the Risk of Stroke and MI
At the 2015 ACR annual meeting in San Francisco, Len Calabrese, DO, of the Cleveland Clinic, gave a plenary session talk linking "shingles" infection to an increased risk of CVA (
Read Article
Plasmacytoid Dendritic Cells Influences Early, But Not Established Lupus
The Journal of Immunology has published the findings of Virginia Tech researchers who have studied plasmacytoid dendritic cells and their ability to induce type I alpha interferon (IFN-α) in lupus. (Citation source: http://buff.ly/1MceeCl)
Read ArticleRituximab's Efficacy May Be Correlated with CD4 T Cell Counts
Rituximab (RTX) is highly effective at B cell depletion and this may be one of several hypothetical ways in which the drug works. B cell numbers (measured as CD19+ B cells) plummet rapidly after the first infusion and stay down for 6-12 months.
Read Article
DSB: ACR 2015 Safety Reports
The following is a compilation of abstracts presented at the 2015 Annual ACR meeting in San Francisco. These were chosen on the basis of impact, quality and safety message.
Read Article
EU Endorses Biosimilar Etanercept (SB4) from Samsung/Biogen
Reuters today reported that a copy of the blockbuster biotech drug Enbrel (SB4) was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators.
Read Article
Biology of Bone Remodeling in Psoriatic Disease
Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.
Read Article
ANCA Levels Predict Relapse in ANCA-Associated Vasculitis
A team of Japanese investigators examine 126 patients with ANCA-associated renal vasculitis to see if ANCA levels would predict disease relapse.
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
Decline in Physician Scientists Ahead
The Journal of Clinical Investigation reports a potential decline in the number of medical researchers in the future.
Read Article
Genetic Basis for Pediatric Autoimmune Diseases
Researchers at CHOP have published their investigations into the heritability of pediatric autoimmune diseases that affects roughly one in 12 persons.
Read Article
Is DLCO Predictive in Rheumatoid Interstitial Lung Disease?
Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Its presence may portend grave outcomes for those affected. The prevalence of ILD in RA ranges from 7.7% to 44% depending on the assessment tools used.
Read Article
Lupus Foundation of America Announces 2015 Award Recipients
Healio reported the newly announced grant recipients from the Lupus Foundation of America.
Read Article
Angiogenic Biomarkers Predict Adverse Outcomes Pregnancies in Lupus
The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.
Read Article
New Drugs, New Hope for Pulmonary Fibrosis
The Wall Street Journal reports that new drug development offers hope for people with idiopathic pulmonary fibrosis, a rare, progressive fibrosing lung disorder that affects nearly 200,000 Americans, mostly middle-aged and older adults.
Read Article
Funding for Rheumatology Research in Decline
The Rheumatology Research Foundation and Rheumatology News report that research projects funded by the National Institutes of Health (NIH) dropped by 52% from 2010 to 2014, while the number funded by private foundations fell by 29% over that period.
Read Article
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
Read Article
JIA Pathogenesis Related to Neutrophils and Epigenetics
Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).
Read Article